CHM.ASX: Quarterly Activities/Appendix 4C Cash Flow Report

Quarterly Activities/Appendix 4C Cash Flow Report

Stock	Chimeric Therapeutics Ltd (CHM.ASX)
Release Time	31 Jul 2026, 3:03 p.m.
Price Sensitive	Yes

This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA. The summaries are generated by large language models so please interpret with care.

Chimeric Therapeutics Q1 FY26 Financial Report and Clinical Updates

Key Points

Phase 1 study of CHM CDH17 shows promising tumour shrinkage results
60% of enrolled patients in CHM CORE-NK trial achieve complete response
Strategic review initiated to maximize value of Chimeric's assets
Closing cash of $0.8M at end of June, with additional $2.27M received in July
Board member Mr. Eric Sullivan retires from the Board

Full Summary

Chimeric Therapeutics (ASX: CHM) provided a comprehensive update on its activities for the quarter ended 30 June 2026. The company reported positive interim data from its Phase 1/2 study of CHM CDH17, showing significant tumor shrinkage in patients at Dose Level 3. Additionally, 60% of patients in the CHM CORE-NK trial achieved complete response. Chimeric also initiated a strategic review to explore options for maximizing the value of its assets. The company ended the quarter with $0.8M in cash and received an additional $2.27M in July. The board also saw the retirement of Independent Non-Executive Director Mr. Eric Sullivan.

Outlook

Chimeric Therapeutics anticipates continued clinical progress and expects to complete the CHM CDH17 study later this year, subject to funding. The strategic review aims to unlock additional value for the company.